News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
744,801 Results
Type
Article (42699)
Company Profile (317)
Press Release (701770)
Multimedia
Podcasts (136)
Webinars (23)
Section
Business (208125)
Career Advice (2106)
Deals (36190)
Drug Delivery (141)
Drug Development (83024)
Employer Resources (183)
FDA (16633)
Job Trends (15333)
News (352470)
Policy (33153)
Tag
2027 BioCapital Elite (1)
2027 BioCapital Standard (1)
2027 BioMidwest Elite (1)
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (2)
2027 Biotech Bay Standard (3)
2027 Biotech Beach Elite (1)
2027 Genetown Elite (3)
2027 Genetown Standard (2)
2027 Pharm Country Elite (2)
2027 Pharm Country Standard (5)
Academia (2630)
Accelerated approval (55)
ADA (45)
Adcomms (29)
Allergies (192)
Alliances (50524)
ALS (223)
Alzheimer's disease (1858)
Antibody-drug conjugate (ADC) (519)
Approvals (17076)
Artificial intelligence (733)
ASCO (334)
Autoimmune disease (336)
Automation (61)
Bankruptcy (365)
Best Places to Work (11762)
BIOSECURE Act (22)
Biosimilars (237)
Biotechnology (208)
Bladder cancer (202)
Brain cancer (77)
Breast cancer (795)
Cancer (6280)
Cardiovascular disease (512)
Career advice (1792)
Career pathing (51)
CAR-T (356)
CDC (62)
Celiac Disease (3)
Cell therapy (969)
Cervical cancer (54)
Clinical research (72557)
Collaboration (2226)
Commercialization (1)
Company closure (5)
Compensation (1497)
Complete response letters (87)
COVID-19 (2780)
CRISPR (114)
C-suite (1242)
Cystic fibrosis (158)
Data (8598)
Decentralized trials (3)
Denatured (38)
Depression (179)
Dermatology (94)
Diabetes (662)
Diagnostics (7045)
Digital health (63)
Diversity (14)
Diversity, equity & inclusion (46)
Drug discovery (354)
Drug pricing (209)
Drug shortages (31)
Duchenne muscular dystrophy (301)
Earnings (93291)
Editorial (76)
Employer branding (23)
Employer resources (156)
Events (123200)
Executive appointments (1141)
FDA (20590)
Fibrodysplasia Ossificans Progressiva (9)
Friedreich's ataxia (20)
Frontotemporal dementia (35)
Funding (1838)
Gene editing (244)
Generative AI (62)
Gene therapy (756)
GLP-1 (1129)
Government (4811)
Grass and pollen (7)
Guidances (416)
Healthcare (19247)
Hematology (194)
HIV (89)
Huntington's disease (62)
IgA nephropathy (110)
Immunology and inflammation (305)
Immuno-oncology (105)
Indications (211)
Infectious disease (3146)
Inflammatory bowel disease (222)
Inflation Reduction Act (15)
Influenza (141)
Intellectual property (315)
Interviews (338)
IPO (16947)
IRA (51)
Job creations (3863)
Job search strategy (1480)
JPM (65)
Kidney cancer (20)
Labor market (116)
Layoffs (594)
Leadership (50)
Legal (8023)
Liver cancer (104)
Longevity (35)
Lung cancer (829)
Lymphoma (473)
Machine learning (64)
Management (59)
Manufacturing (1141)
Marketing (1)
MASH (217)
Medical affairs (1)
Medical device (14012)
Medtech (14172)
Mergers & acquisitions (20551)
Metabolic disorders (1670)
mRNA (235)
Multiple sclerosis (199)
NASH (17)
Neurodegenerative disease (459)
Neuropsychiatric disorders (114)
Neuroscience (3496)
Neurotech (1)
NextGen: Class of 2026 (6592)
Non-profit (4560)
Now hiring (82)
Obesity (772)
Opinion (316)
Ovarian cancer (240)
Pain (266)
Pancreatic cancer (345)
Parkinson's disease (394)
Partnered (35)
Patents (630)
Patient recruitment (746)
Peanut (66)
People (60777)
Pharmaceutical (72)
Pharmacy benefit managers (34)
Phase 1 (22666)
Phase 2 (32025)
Phase 3 (23697)
Pipeline (9693)
Policy (347)
Postmarket research (2581)
Preclinical (9638)
Press Release (64)
Prostate cancer (336)
Psychedelics (58)
Radiopharmaceuticals (354)
Rare diseases (1164)
Real estate (6155)
Recruiting (72)
Regulatory (26053)
Reports (61)
Research institute (2447)
Resumes & cover letters (359)
Rett syndrome (42)
RNA editing (24)
RSV (90)
Schizophrenia (184)
Series A (311)
Series B (228)
Service/supplier (11)
Sickle cell disease (118)
Special edition (29)
Spinal muscular atrophy (167)
Sponsored (50)
Startups (3740)
State (2)
Stomach cancer (18)
Supply chain (138)
Tariffs (94)
The Weekly (96)
Vaccines (1163)
Venture capital (123)
Weight loss (498)
Women's health (138)
Worklife (24)
Date
Today (93)
Last 7 days (505)
Last 30 days (2702)
Last 365 days (30840)
2026 (15743)
2025 (30597)
2024 (35742)
2023 (40679)
2022 (51812)
2021 (56354)
2020 (54574)
2019 (47015)
2018 (35409)
2017 (32713)
2016 (32118)
2015 (38167)
2014 (32052)
2013 (26961)
2012 (29102)
2011 (29750)
2010 (27754)
Location
Africa (766)
Alabama (98)
Alaska (7)
Arizona (365)
Arkansas (15)
Asia (41968)
Australia (6683)
California (13953)
Canada (3930)
China (1544)
Colorado (597)
Connecticut (611)
Delaware (433)
Europe (89855)
Florida (2123)
Georgia (443)
Hawaii (3)
Idaho (63)
Illinois (1139)
India (97)
Indiana (630)
Iowa (24)
Japan (593)
Kansas (134)
Kentucky (52)
Louisiana (59)
Maine (76)
Maryland (1673)
Massachusetts (10086)
Michigan (376)
Minnesota (755)
Mississippi (6)
Missouri (148)
Montana (33)
Nebraska (30)
Nevada (148)
New Hampshire (84)
New Jersey (3660)
New Mexico (31)
New York (3671)
North Carolina (1821)
North Dakota (9)
Northern California (7029)
Ohio (416)
Oklahoma (24)
Oregon (42)
Pennsylvania (2767)
Puerto Rico (32)
Rhode Island (52)
South America (1137)
South Carolina (86)
South Dakota (2)
Southern California (5525)
Tennessee (224)
Texas (2246)
United States (49448)
Utah (413)
Vermont (2)
Virginia (346)
Washington D.C. (81)
Washington State (1130)
West Virginia (4)
Wisconsin (136)
Wyoming (2)
744,801 Results for "shanghai zhimeng biopharma inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Podcast
Moderna’s FDA adcomm, IPO mania, biopharma layoffs, more
Moderna appears to have aligned with the FDA ahead of an advisory committee meeting for its mRNA-based flu vaccine, which the regulator initially turned away in February; biotech IPOs are going gangbusters, including two new records raises in as many weeks; layoffs continue across biopharma; plus much more.
June 17, 2026
·
2 min read
·
Jef Akst
Career Advice
The top 12 companies hiring in biopharma now
Looking for a biopharma job? Check out the
BioSpace
list of 12 top companies hiring life sciences professionals like you.
June 4, 2026
·
1 min read
·
Angela Gabriel
Press Releases
COSCIENS Biopharma Inc. Announces Results of Shareholder Meeting and Appointment of Full-Time CEO
June 18, 2026
·
4 min read
Artificial intelligence
Lilly, BMS, Incyte strike deals to keep biopharma’s AI integration rolling
A trifecta of newly inked tech partnerships—from Eli Lilly, Bristol Myers Squibb and Incyte—exemplify the increasingly central role that AI is playing in drug development.
May 21, 2026
·
3 min read
·
Tristan Manalac
Artificial intelligence
Novartis CEO joins Anthropic board, embedding AI in the heart of biopharma
In recent months, Anthropic has been building more and more ties with the biopharma industry, including partnerships with Big Pharma companies such as Sanofi, Novo Nordisk and AbbVie.
April 16, 2026
·
2 min read
·
Tristan Manalac
Press Releases
COSCIENS Biopharma Inc. Reports Q1 2026 Results
May 13, 2026
·
8 min read
FDA
Zhimeng Biopharma CB03 Received Orphan Drug Designation from the US FDA - A Potassium Ion Channel Opener for Amyotrophic Lateral Sclerosis
Shanghai Zhimeng Biopharma, Inc. (“Zhimeng”), announced that one of its innovative small-molecule KCNQ2/3 selective opener compounds (CB03), developed for the treatment of amyotrophic lateral sclerosis (ALS), received orphan drug designation (ODD) from US FDA.
October 20, 2023
·
3 min read
Press Releases
Sunshine Biopharma Inc. Announces Pricing of $6.0 Million Public Offering
May 18, 2026
·
4 min read
Press Releases
Sunshine Biopharma Inc. Announces Closing of up to $18.0 Million Public Offering
May 19, 2026
·
4 min read
Press Releases
Aspire Biopharma Holdings, Inc. Announces Approval Of Reverse Stock Split Ratio
May 7, 2026
·
4 min read
1 of 74,481
Next
